ArticleBioresources and bioprocessing2026
Solanum nigrum L.-derived nanovesicles as novel nanotherapeutics suppressing prostate cancer progression via senescence-based antitumor activity.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Current therapies for prostate cancer are limited by toxicity and acquired resistance, motivating development of biocompatible nanotherapeutics. Here, Solanum nigrum L.-derived nanovesicles (SDNVs) were isolated and characterized, showing a mean diameter of 93.4 ± 0.2 nm and a particle concentration of (4.2 ± 0.4) × 1011/mL. SDNV uptake, antitumor activity, and safety were assessed in PC-3 and RWPE-1 cells, while efficacy and biodistribution were further evaluated in a subcutaneous PC-3 xenograft mouse model following oral administration. SDNVs were readily internalized by PC-3 cells and suppressed viability, proliferation, and migration while inducing apoptosis. Senescence and cytotoxicity were not observed in RWPE-1 cells, indicating tumor-selective activity. The underlying mechanism was further investigated by transcriptome sequencing, followed by quantitative PCR, Western blotting, and pharmacologic rescue with the p53 inhibitor pifithrin-α (PFT-α). Transcriptomic analysis revealed 5058 differentially expressed genes, and further indicated activation of the p53/p21 axis and promoted cellular senescence in PC-3 cells after SDNV treatment. In vivo, oral SDNVs significantly reduced xenograft growth and showed no evident histopathologic toxicity in major organs. Collectively, SDNVs represent a plant-derived, biocompatible nanotherapeutic platform that selectively restrains prostate cancer growth via p53/p21-mediated senescence, supporting further development of senescence-targeting SDNV-based interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.